YM155 (Sepantronium Bromide)

For research use only.

Catalog No.S1130

101 publications

YM155 (Sepantronium Bromide) Chemical Structure

Molecular Weight(MW): 443.29

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 447 In stock
USD 770 In stock
USD 1270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's YM155 (Sepantronium Bromide) has been cited by 101 publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLmfplDPzJiaB?= NEjQRmtFVVOR NVrk[Xk2UUN3ME2wMlAxQSEEsTCwMlAxODlizszN Mo\2NlU3PTl5M{G=
M-07e NX;iRWxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPKO|IhcA>? MknKSG1UVw>? NIL6dZVKSzVyPUCuNFQxKMLzIECuNFE{KM7:TR?= MYiyOVY2QTd|MR?=
THP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XLfFczKGh? MnLPSG1UVw>? NWTlb2tnUUN3ME2wMlA2OSEEsTCwMlAyOyEQvF2= NHrVVngzPTZ3OUezNS=>
CMK MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\m[GI4OiCq MnjSSG1UVw>? MYLJR|UxRTBwMEWzJOKyKDBwMEC5JO69VQ>? M{nMc|I2PjV7N{Ox
MV4-11 M2LwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3DPW04OiCq NYm2VY1LTE2VTx?= M3j4RmlEPTB;MD6wOVUhyrFiMD6wNlgh|ryP M1zXR|I2PjV7N{Ox
AML-193 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xt[FczKGh? NUXyRnZVTE2VTx?= M2XnS2lEPTB;MD60OlIhyrFiMD6wOlAh|ryP M2\WUlI2PjV7N{Ox
HL-60 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n6dFczKGh? NUD4dmh5TE2VTx?= M1rLV2lEPTB;MD6wNFEhyrFiMD6wNFAzKM7:TR?= NYjBb|JGOjV4NUm3N|E>
ML-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HZWFczKGh? M2\uR2ROW09? MV7JR|UxRTBwMEC5JOKyKDBwMECyJO69VQ>? MUiyOVY2QTd|MR?=
OCI/AML3 NUW4V49{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj6O|IhcA>? MX;EUXNQ MofFTWM2OD1yLkCxNUDDuSByLkCwNkDPxE1? NXniNplQOjV4NUm3N|E>
HEL NVPD[INLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe1TGo4OiCq MlnYSG1UVw>? M{XwcGlEPTB;MD61OVkhyrFiMD6wN|gh|ryP MVOyOVY2QTd|MR?=
ME-1 NEfp[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ribVczKGh? MWHEUXNQ NWfKeFd4UUN3ME2wMlY5PCEEsTCwMlE4QSEQvF2= NGi2VXMzPTZ3OUezNS=>
THP-1 NGTxWFRCeG:ydH;zbZMhSXO|YYm= MWGxxsDPxE1? MYK3NkBp MkLISG1UVw>? NWnlb2F[cW6mdXPld{BieG:ydH;zbZM> NY\qe497OjV4NUm3N|E>
M-07e MmC4SpVv[3Srb36gRZN{[Xl? M4XCe|DjiJNzwrFOwG0> M3vHdVczKGh? M{m3dmROW09? M2flXIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NHe5UFEzPTZ3OUezNS=>
THP-1 NVvSUmJoTnWwY4Tpc44hSXO|YYm= MX:w5qCUOcLizszN MnXTO|IhcA>? NIHSO4lFVVOR MWHpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw NXjOVos6OjV4NUm3N|E>
CMK MWTGeY5kfGmxbjDBd5NigQ>? NHy4UZAx6oDVMdMg{txO NH;OPZg4OiCq NFLYRWtFVVOR Moi5bY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= MW[yOVY2QTd|MR?=
AML-193 NVPTb4drTnWwY4Tpc44hSXO|YYm= M1q5NVDjiJNzwrFOwG0> MX:3NkBp NYjCbVNwTE2VTx?= NYj5W4FPcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> M{\OblI2PjV7N{Ox
Kasumi-1 MmDrSpVv[3Srb36gRZN{[Xl? NVPMV3FPOOLCk{JCpO69VQ>? M2rj[FczKGh? NGrzfpJFVVOR NEe3V5BqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu NHTMTlIzPTZ3OUezNS=>
MV4-11 MoO5SpVv[3Srb36gRZN{[Xl? NInxeoEx6oDVMdMg{txO Mn\DO|IhcA>? NHvhVmJFVVOR NILxR5JqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu MVOyOVY2QTd|MR?=
MUG-Chor  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOwMVUh|ryP M2TU[|I1NzR6IHi= NUXlZohlUUN3ME23MlA26oDLbl2g[o9zKDR6aB?= NYDTZ4RDOjV4NECxPFU>
U-CH1  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TyeVAuPSEQvF2= MXKyOE81QCCq NGP5U|dKSzVyPUmuNFPjiImwTTDmc5IhPDiq NYi1SFd4OjV4NECxPFU>
KATOIII MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7aNVAwOjBibl2= NHHXd4Q1QCCq M3frN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkPXNlU3OzVyNUW=
AGS  M1:yc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKxNE8zOCCwTR?= MWO0PEBp MoLqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVeyOVY{PTB3NR?=
SACC-83 MnrMSpVv[3Srb36gRZN{[Xl? NYLTZ2x3PSCwTR?= NHnnfog1QCCq NInOUWhl\WO{ZXHz[ZMhdnWlbHXhdkBmgHC{ZYPzbY9vKG:oIFjJSk0y|rF? MlP3NlU1QDV4M{W=
INA-6 NVG3fVhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvnTpgxNTVyMDDuUS=> NV3MboxnPDhiaB?= NF;hPZlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXGyOVI6Pjl5OB?=
U-266 MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2wMVUxOCCwTR?= M1LQOFQ5KGh? MUfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M33PWlI2Ojl4OUe4
MOLP-8 NV\WclR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYewMVUxOCCwTR?= MnrlOFghcA>? M1nFW4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXyyOVI6Pjl5OB?=
HG-1 NGPhOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LnblAuPTByIH7N M4P4TFQ5KGh? Ml7hbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1[yfFI2Ojl4OUe4
NCI-H929 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Xyc|AuPTByIH7N M2\hb|Q5KGh? NYTBXodqcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVTacWk4OjV{OU[5O|g>
OPM-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGwMVUxOCCwTR?= MnjaOFghcA>? MoHDbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYOyOVI6Pjl5OB?=
L-363 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWiwMVUxOCCwTR?= MlfUOFghcA>? M2XheIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnXXNlUzQTZ7N{i=
MOLP-2 M2nobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG3THMxNTVyMDDuUS=> MVm0PEBp MnSzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{OySlI2Ojl4OUe4
KMS-12-BM NXjMOXA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED5NncxNTVyMDDuUS=> M{TxZ|Q5KGh? NFjPNVRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUnrdZpbOjV{OU[5O|g>
SK-MM-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;mXoZEOC13MECgcm0> NVPNclZRPDhiaB?= MoLUbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1TjPVI2Ojl4OUe4
U-266 MmPwRZBweHSxc3nzJGF{e2G7 M3XLXFAuPTBibl2= MkjSNlQhcA>? NXyzUINCcW6mdXPld{BieG:ydH;zbZM> M4fGN|I2Ojl4OUe4
INA-6  MljsRZBweHSxc3nzJGF{e2G7 NYrt[lNwOC13MDDuUS=> NXjhb24zOjRiaB?= NFPLWpVqdmS3Y3XzJIFxd3C2b4Ppdy=> NIPITFQzPTJ7Nkm3PC=>
MCF7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[4dVczKGh? NVHwNmlSUUN3ME2xN{DDuSB4IH7N MorBNlUzOjB{MkW=
MCF7-TamR6 Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L3clczKGh? M4TYc2lEPTB;ODFCtUA3KG6P M1rLXFI2OjJyMkK1
MCF7-TamR7 NXWx[2hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO3NkBp Mn23TWM2OD16INMxJFMhdk1? Mk\KNlUzOjB{MkW=
MCF7-TamR8 M37vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPXNok4OiCq MX7JR|UxRTF3INMxJFYhdk1? MoLUNlUzOjB{MkW=
MCF7-TamC3 NHTJV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzk[2g4OiCq M1ri[mlEPTB;NjFCtUA{KG6P M{[2[VI2OjJyMkK1
MCF7-TamC6 M3HIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrUOHY4OiCq MUPJR|UxRTZiwsGgNE4yKG6P MnzNNlUzOjB{MkW=
MDA-MB-231 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPIeJZXPzJiaB?= NGnSZlJKSzVyPUWgxtEhOSCwTR?= M4XMbVI2OjJyMkK1
SK-BR-3 NYjxZWtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj5O|IhcA>? NIHRSplKSzVyPUegxtEhOC5|IH7N NXvwTW04OjV{MkCyNlU>
Eca109 NX3FN2d1TnWwY4Tpc44hSXO|YYm= MWSxMVUxKG6P M1rMWFQ5KGh? Mny0SG1UVw>? MXnzeZBxemW|c3XzJJN2en[rdnnuJIV5eHKnc4Ppc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NFzZb|czPTF|OUO5OS=>
TE13 M2e4OmZ2dmO2aX;uJGF{e2G7 NF\uOlcyNTVyIH7N NHHFUGs1QCCq NVjYb5JGTE2VTx?= NIntT3h{fXCycnXzd4V{KHO3co\peolvKGW6cILld5Nqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlvjNlUyOzl|OUW=
Eca109 M3TWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj4NE0yODBibl2= MUSyOE81QCCq NYX1[JA1TE2VTx?= MWLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NI[zTXgzPTF|OUO5OS=>
TE13 MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrYeZJ5OC1zMECgcm0> NYHi[2s5OjRxNEigbC=> MWLEUXNQ MoPT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2TWZ|I2OTN7M{m1
MT-3 MYjLbY5ie2ViQYPzZZk> MV63NkBp NIfleGVFVVOR NF[1VYVKSzVyPUKuPFYhyrFiMD61OEBvVSCob4KgSHI1KGW6cILld5Nqd25? NXq5[4Y2OjR6Nk[1PFU>
MDA-MB-468 M{O0O2tqdmG|ZTDBd5NigQ>? NVjFbFk{PzJiaB?= M1nWRWROW09? Mn35TWM2OD1yLkGxJOKyKDBwMEGgcm0h\m:{IFTSOEBmgHC{ZYPzbY9v NFmwclQzPDh4NkW4OS=>
SUM-159 NH21NIVMcW6jc3WgRZN{[Xl? Mon0O|IhcA>? NFHvOHBFVVOR MV;JR|UxRTFwN{KgxtEhOC5|MzDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> NVvhbpRPOjR6Nk[1PFU>
MT-3 NV7yWFh7U2mwYYPlJGF{e2G7 MoDNO|IhcA>? NYixNmJYTE2VTx?= Mk\kTWM2OD13ND6xNUDDuSB2LkOyJI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? NEKzUokzPDh4NkW4OS=>
MDA-MB-468 NEjZdZNMcW6jc3WgRZN{[Xl? MU[3NkBp M3rVOGROW09? NFfybVhKSzVyPUCuNFchyrFiMD6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? MnnPNlQ5PjZ3OEW=
SUM-159 M2\WWGtqdmG|ZTDBd5NigQ>? MXq3NkBp NWG3UFVUTE2VTx?= MoTUTWM2OD14OT60JOKyKDRwMkOgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v NUXxPHNjOjR6Nk[1PFU>
MT-3 + NAC MWrLbY5ie2ViQYPzZZk> NIrpUWM4OiCq M2jpWGROW09? NFH3ZVBKSzVyPUW2MlIhyrFiMj6wO{BvVSCob4KgSHI2KGW6cILld5Nqd25? NEjoc2wzPDh4NkW4OS=>
MT-3 + SB203580 MYDLbY5ie2ViQYPzZZk> MlfnO|IhcA>? NIfOSW9FVVOR M{XR[WlEPTB;M{iuOFEhyrFiNT6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? MUGyOFg3PjV6NR?=
DB MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\jfFQyOCCwTR?= M2C2Z|I1KGh? M4W1RmROW09? MXvpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= MUCyOFQ5PjV7NR?=
SU-DHL-8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjsNVAhdk1? Ml3HNlQhcA>? M2\te2ROW09? NWrmTHpGcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v NIHze2IzPDR6NkW5OS=>
WSU-DLCL2 MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVziUIJFOTBibl2= NHfDe5kzPCCq M3T5SWROW09? NX31bGdxcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v NHrCRVgzPDR6NkW5OS=>
ACC-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LxOFAuOTByIH7N MUeyOEBp M3myR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYXT[oREOjR|N{C5PVU>
ACC-2 MX3BdI9xfG:|aYOgRZN{[Xl? MUGwMVIxKG6P NEm2fHkzPCCq NEnie4FqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGnrRWczPDN5MEm5OS=>
ACC-2 NV3xS|Q4TnWwY4Tpc44hSXO|YYm= Mne2NE0zOCCwTR?= NYLYc4ZyOjRiaB?= MXrpcoNz\WG|ZYOgeIhmKGOxbo\ldpNqd25ib3[gUGM{USC2bzDMR|NKUQ>? MV[yOFM4ODl7NR?=
BFTC905 M{L5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHSemYxNTFyMECgcm0> NVfDVGFlPDhiaNMg NVTQ[YdPTE2VTx?= MnT1TWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NV3PUYEyOjR{OUe2OFQ>
T24 NGHMdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm0NE0yODByIH7N MXq0PEBpyqB? M4\IfmROW09? M{DpU2lEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYW5O5VCOjR{OUe2OFQ>
TSGH8301  NXLMOlVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HQTlAuOTByMDDuUS=> Mo\uOFghcMLi NYf1SlJKTE2VTx?= M2TBO2lEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUDJfY5OOjR{OUe2OFQ>
BFTC909 M1\MNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vjdlAuOTByMDDuUS=> MUC0PEBpyqB? M1u3ZmROW09? MXHJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFjBZ28zPDJ7N{[0OC=>
BFTC905 NVjH[VYySXCxcITvd4l{KEG|c3H5 MXyyNEBvVQ>? MWW0PEBp MUjEUXNQ MmDLbY5lfWOnczDhdI9xfG:|aYO= NX70XG4yOjR{OUe2OFQ>
BFTC905 MoXtSpVv[3Srb36gRZN{[Xl? NHzqeVQzOCCwTR?= NIW5NHk1QCCq Mn2xSG1UVw>? MlrT[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEO0JvSVm= M3:3bFI1Ojl5NkS0
A2780p MlfhSpVv[3Srb36gRZN{[Xl? NWTrSZNPOC1zMECgcm0> M4jZdlI1KGh? MkDqSG1UVw>? NU\rbGhMcW6mdXPld{BUfXK4aY\pckBld3ewcnXneYxifGmxbtMg NWfjfIVPOjR{NkK4O|U>
A2780cis M2\kZWZ2dmO2aX;uJGF{e2G7 NGLrPIIxNTFyMDDuUS=> NFzpcIYzPCCq M3HybWROW09? M3T6folv\HWlZYOgV5Vzfmm4aX6g[I94dnKnZ4XsZZRqd28EoB?= NWPHflZbOjR{NkK4O|U>
A2780p NVOwVphYSXCxcITvd4l{KEG|c3H5 NHzoOIk2NTFyMDDuUS=> NYHabXJWOjRxNEigbC=> MnLtSG1UVw>? NUPxOYhFcW6lcnXhd4V{KGGyb4D0c5NqeyCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NXjzeFNoOjR{NkK4O|U>
A2780cis MV\BdI9xfG:|aYOgRZN{[Xl? M2nuelUuOTByIH7N M1njcFI1NzR6IHi= M2D1[2ROW09? MXXpcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy MUmyOFI3Ojh5NR?=
SH-SY5Y M1TU[2Fxd3C2b4Ppd{BCe3OjeR?= MXSxM|ExNzFyMDFCuW0> M4nVTVczKGh? MXfEUXNQ NHjUU5NqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHnSco0zPDJ3NEW2NC=>
HL-60 NEfiUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPhTnQ4OsLiaB?= NVHHeY9yTE2VTx?= MUjJR|UxRTBwMzDuUS=> NWrpbos1OjN4MUi4OlI>
U937  MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn4Tm04OsLiaB?= M3fV[mROW09? M4DkTGlEPTB;MD64JI5O NH;rUJkzOzZzOEi2Ni=>
HL-60  M3OxNmZ2dmO2aX;uJGF{e2G7 NF7lNGQyyqEQvF2= MYO2M|EzNzJ2IHi= MWDEUXNQ NXLpV2JHcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4Yhe3W{dnn2bY4> NHrlbZMzOzZzOEi2Ni=>
U937  NVXvXHlKTnWwY4Tpc44hSXO|YYm= MVSxxsDPxE1? M4fFVVYwOTJxMkSgbC=> Mk\qSG1UVw>? NHPsTHBqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kB{fXK4aY\pci=> NYf4TFhTOjN4MUi4OlI>
HL-60 NHTHeFNCeG:ydH;zbZMhSXO|YYm= Mlm2NE4yNzFizszN NVLaWm5MQCCq NVry[o1kTE2VTx?= NXLzT25zcW6mdXPld{BieG:ydH;zbZM> M{HLeVI{PjF6OE[y
Sk-NEP-1  MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\oNU0yODByMDDuUS=> MkDHNlQhcA>? M2PYdGROW09? MUPJR|UxRTFyMDDuUS=> MXqyN|I3PzZ7OR?=
SK-NEP-1  NX\UUo9vSXCxcITvd4l{KEG|c3H5 MmfQOVAwOTByIH7N MoSxNVIwOjRiaB?= NYjGS5hHTE2VTx?= M{HETolv\HWlZYOgZZBweHSxc3nz M3fRV|I{OjZ5Nkm5
TC-32 M1HLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTYbmgxNjFvMUCwNEBvVQ>? MX3FR|UxRTNwMDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2TPfFIzQTZzN{[z
TC-71 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\j[phGOC5zLUGwNFAhdk1? NWG0eIt3TUN3ME21Mlchdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NEjNXFQzOjl4MUe2Ny=>
SK-ES-1 M2HtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCzN4ozOC5zLUGwNFAhdk1? MoTYSWM2OD1{Lkigcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MknXNlI6PjF5NkO=
RD-ES NGLYVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\UdYlIOC5zLUGwNFAhdk1? MkTJSWM2OD14LkKgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFP5WpgzOjl4MUe2Ny=>
HEK293 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHYbY1EOC5zLUGwNFAhdk1? MkLqSWM2OD1{Mz6wJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Ml7SNlI6PjF5NkO=
M059J MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy3WnAxNTVyIH7N NFvMdHE1QCCq M4f6dolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnzXNlI4PzBzMUC=
M059K NXn6eY06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDqbooxNTVyIH7N M2\nXFQ5KGh? MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3PtZlIzPzdyMUGw
M059J NIP6T4tCeG:ydH;zbZMhSXO|YYm= NXj6NGNpOzBibl2= NFTJNZozPCCq NF;yWZdqdmS3Y3XzJIFxd3C2b4Ppdy=> M3Xj[lIzPzdyMUGw
M059K NVnKUY5YSXCxcITvd4l{KEG|c3H5 M2jPW|MxKG6P NF3EbnczPCCq M1G3Oolv\HWlZYOgZZBweHSxc3nz MVeyNlc4ODFzMB?=
PANC-1 MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXUVlQxNjBzLUGwNFAhdk1? MoPvOFghcA>? NV;5O|d1UUN3ME2zMlY6KG6P M3XwOFIzPzJ|OEex
MIAPaCa-2 M4TyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3DNE4xOS1zMECwJI5O Mo\IOFghcA>? NXjDdHRRUUN3ME2yPU4{PiCwTR?= MkT4NlI4OjN6N{G=
BxPC-3 NE\kWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HOUVAvODFvMUCwNEBvVQ>? MofUOFghcA>? MVPJR|UxRTNyLkK2JI5O NVjkN5hUOjJ5MkO4O|E>
PANC-1 MXzGeY5kfGmxbjDBd5NigQ>? MoPiNE0yODByIH7N M2LXXVI1KGh? MlrPbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDYTWFRKGGwZDDzeZJ3cX[rbjDlfJBz\XO|aX;u NUCx[lRjOjJ5MkO4O|E>
MIAPaCa-2 M3:5cGZ2dmO2aX;uJGF{e2G7 NX;OZ5dxOC1zMECwJI5O MUKyOEBp MXfpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= NE\6fHAzOjd{M{i3NS=>
BxPC-3 M2m3XGZ2dmO2aX;uJGF{e2G7 NFvIe|AxNTFyMECgcm0> NVLYdow{OjRiaB?= M{nWNolv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> NHvPPIEzOjd{M{i3NS=>
RPMI-7951 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7EeItYT0l3ME2zMlIhdk1? NWHhTotMOjF5M{e1NFI>
SK-MEL-5 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{THcmdKPTB;ND6yJI5O NXP1OGRIOjF5M{e1NFI>
A375 NGqyUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG1TZZPT0l3ME22MlMhdk1? NXnxNZZ7OjF5M{e1NFI>
SK-MEL-28 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULHTVUxRTdwNjDuUS=> MUSyNVc{PzVyMh?=
SK-MEL-2 M4nVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TnbmdKPTB;MUGgcm0> NEi1NY0zOTd|N{WwNi=>
DB M{nqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[0POKhcA>? M{TzUmdKPTB;Mz61JI5O NXXzVIVOOjF{M{e1NFg>
Pfeiffer M1zLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX6OFjDqGh? M3PDe2dKPTB;Mz65JI5O NHHi[YEzOTJ|N{WwPC=>
SU-DHL-5 M3LDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTrenN5PDkEoHi= NIC5SYtIUTVyPUCuNlMhdk1? Ml;jNlEzOzd3MEi=
SU-DHL-8 M{XWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\ZbVQ5yqCq M1L3dWdKPTB;MT60JI5O MUmyNVI{PzVyOB?=
WSU-DLCL-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPLXYpLPDkEoHi= NF7QVmpIUTVyPUGuOEBvVQ>? M33DclIyOjN5NUC4

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

- Collapse
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A
Smiles [Br-].COCC[N]1C(=[N+](CC2=CN=CC=N2)C3=C1C(=O)C4=C(C=CC=C4)C3=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155|YM155 ic50|YM155 price|YM155 cost|YM155 solubility dmso|YM155 purchase|YM155 manufacturer|YM155 research buy|YM155 order|YM155 mouse|YM155 chemical structure|YM155 mw|YM155 molecular weight|YM155 datasheet|YM155 supplier|YM155 in vitro|YM155 cell line|YM155 concentration|YM155 nmr|YM155 in vivo|YM155 clinical trial|YM155 inhibitor|YM155 Apoptosis inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID